Home » Topics » Regulatory » EMA

EMA
RSS

European orphan drug designation for Epidiolex for Lennox-Gastaut syndrome

March 30, 2017

EMA committee recommends approval of dinutuximab beta for the treatment of high-risk neuroblastoma

March 29, 2017

Refixia recommended for approval in E.U.

March 27, 2017

EMA validates regulatory filing of tildrakizumab in Europe

March 27, 2017

Opdivo approved in Japan for head and neck cancer, recommended for approval in E.U.

March 27, 2017

EMA committee recommends approval of Trumenba

March 27, 2017

EMA accepts Shionogi's MAA submission for naldemedine

March 27, 2017

EMA committee recommends approval of Keytruda for classical Hodgkin's lymphoma

March 27, 2017

EMA committee recommends approval of Axumin for use in prostate cancer

March 27, 2017

EMA grants orphan drug designation to NiCord in HSCT

March 24, 2017

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...